High sustained response rate for glecaprevir, pibrentasvir in HCV
(HealthDay)—For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according ...
Oct 12, 2017
0
0